Depo-Provera Litigation (Intracranial Meningioma / Brain Tumor)

Depo-Provera (medroxyprogesterone acetate) is an injectable hormonal contraceptive manufactured by Pfizer, administered as an intramuscular injection every three months. It has been one of the most widely used long-acting contraceptives worldwide since its FDA approval in 1992, with an estimated 2.6 million women in the United States using the product at its peak.

Multiple studies — including large-scale French pharmacovigilance research and European epidemiological studies — have linked long-term progestogen exposure to a significantly increased risk of intracranial meningioma. Meningiomas are tumors that grow from the meninges, the protective membranes surrounding the brain and spinal cord. While typically classified as benign, meningiomas can cause serious symptoms including seizures, vision loss, hearing loss, cognitive impairment, weakness, and personality changes depending on their location and size. Treatment often requires complex neurosurgery and/or radiation therapy.

The scientific basis for the litigation rests on a well-established biological mechanism: meningiomas are known to express progesterone receptors, meaning they can be directly stimulated and promoted by progestogenic hormones — the class of hormones to which medroxyprogesterone acetate belongs. This receptor-mediated relationship has been confirmed by decades of research in neuro-oncology.

The FDA issued a safety communication in 2023 acknowledging the meningioma risk associated with prolonged progestogen exposure. However, plaintiffs allege that the scientific evidence supporting this risk was available much earlier — with European studies dating back to the 2010s — and that Pfizer failed to update its labeling or warn prescribing physicians and patients in a timely manner.

The litigation carries particular significance because Depo-Provera has been disproportionately prescribed to women in underserved communities and lower-income populations, and has been used extensively in institutional settings including correctional facilities.

The link between progestogens and meningioma has been established through multiple lines of evidence over the past two decades.

A pivotal 2024 study published in The BMJ — a French national case-control study involving millions of women — found significantly elevated meningioma risk associated with prolonged use of several progestogens, including medroxyprogesterone acetate (the active ingredient in Depo-Provera). Earlier French research, including a landmark 2022 study, had already established strong associations between other progestogens (cyproterone acetate and nomegestrol acetate) and meningioma, leading to regulatory action and product withdrawals in Europe.

The biological mechanism is well understood: approximately 70-80% of meningiomas express progesterone receptors (PR). Progestogenic hormones bind to these receptors and can stimulate tumor growth. This receptor-mediated pathway explains why meningiomas are significantly more common in women than men and why they tend to grow during pregnancy (when progesterone levels are naturally elevated).

Laboratory studies have demonstrated that medroxyprogesterone acetate has particularly strong progestogenic activity — approximately 10-20 times more potent than natural progesterone — which may contribute to its meningioma risk relative to other hormonal contraceptives.

The FDA issued a safety communication in 2023 regarding the meningioma risk. European regulatory agencies have taken more aggressive action, with France requiring updated labeling and monitoring protocols for progestogen-containing medications.

Research is ongoing to determine the dose-response relationship and the extent to which meningioma risk decreases after discontinuation of the drug.

Women who used Depo-Provera (medroxyprogesterone acetate injections) for extended periods — typically one year or more of continuous use — and were subsequently diagnosed with intracranial meningioma or multiple meningiomas may be affected.

Because meningiomas are slow-growing tumors, symptoms may not appear for years or even decades after the period of Depo-Provera use. Women who used the product in the past and have since been diagnosed with meningioma should consider whether the timing aligns with their period of use.

This eligibility information is general and informational only. Whether you have a viable legal claim depends on the specific facts of your situation and the laws of your jurisdiction. Consult a licensed attorney.

The Judicial Panel on Multidistrict Litigation centralized federal Depo-Provera cases on February 7, 2025, as MDL No. 3140 in the Northern District of Florida before Judge M. Casey Rodgers, who previously managed the 3M Combat Arms earplug MDL. As of September 1, 2026, 6,403 cases were pending.

Pfizer argues that the claims are preempted by federal drug-labeling law. After the Depo-Provera label was updated in December 2025 to address meningioma risk, the court ordered supplemental briefing on how the change affects that defense.

On June 15, 2026, the parties reported a global settlement in principle. No dollar amount, eligibility criteria or claims process has been made public, and the agreement must still be finalized. The court vacated the first bellwether trial date and reset the general-causation and preemption hearing for July 27, 2026.

Pfizer has stated that Depo-Provera's FDA-approved labeling includes information about potential risks and that the product's benefit-risk profile remains favorable for its approved indications. The company argues that the meningioma risk data — particularly from French studies — involves different patient populations, different progestogens, and different dosing regimens, and may not be directly applicable to Depo-Provera as used in the United States.

Pfizer has challenged causation through expert testimony arguing that the epidemiological evidence is insufficient to establish that Depo-Provera caused meningiomas in individual plaintiffs, and has argued that the claims are preempted by federal law. The company may also argue that the FDA's 2023 safety communication demonstrates the regulatory system working as intended.

Greenstone LLC, a Pfizer subsidiary that manufactured generic medroxyprogesterone acetate, is also named as a defendant.

Pfizer and the MDL's plaintiffs' leadership reached a global settlement in principle on June 15, 2026. No dollar amount, payment matrix or claims process has been announced, and the settlement must be finalized before any payments can be made.

Past settlement amounts in other mass tort litigations are not a guarantee of results in this case.